Category: ALK Positive News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards
To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program WASHINGTON, DC (December 1, 2022)— Patient organization […]
-
Groups Award Two Grants for ALK-positive Lung Cancer Research
(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are […]
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. […]
-
WE NEED YOUR INFO: Take part in our longitudinal survey of ALK+ Cancer Patients
More participants = more data = better research = more life!We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study […]
-
ALK+ Summit 2022 in Denver, CO was largest Summit yet!!
Date: July 29th-31st Attendees: in-person: 250 Virtual: 850 The ALK Positive annual summit was once again a huge success! This year the event was held both in […]
-
Dr. Kenneth Culver named Director of Research & Clinical Affairs for ALK Positive Inc.
We are excited to welcome Dr. Kenneth Culver as our first Director of Research & Clinical Affairs! Dr. Culver graduated from the University of Iowa College of Medicine in 1981. […]
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two […]
-
The Latest & Greatest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from […]
-
ALK Positive Inc. at ASCO (June 3-7, 2022)
“Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was […]
-
The latest from ALK Positive Inc.
May 14, 2022 ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of […]
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the […]